Abstract
Gastrointestinal cancer treatment is based more on molecular biology that has provided increasing knowledge about cancer pathogenesis on which targeted therapy is being developed. Precisely, targeted therapy is defined as a “type of treatment that uses drugs, such as monoclonal antibodies or tyrosine kinase inhibitors, to identify and attack specific cancer cells”. Nowadays, the United States Food and Drug Administration has approved many targeted therapies for gastrointestinal cancer treatment, as many are in various phases of development as well. In a previous review we discussed the main monoclonal antibodies used and studied in gastrointestinal cancer. In addition to monoclonal antibodies, tyrosine kinase inhibitors represent another class of targeted therapy and following the approval of imatinib for gastrointestinal stromal tumours, other tyrosine kinase inhibitors have been approved for gastrointestinal cancers treatment such as sunitinib, regoragenib, sorafenib and erlotinib. Moving forward, the purpose of this review is to focus on the efficacy data of main tyrosine kinase inhibitors commonly used in the personalized treatment of each gastrointestinal tumour and to provide a comprehensive overview about experimental targeted therapies ongoing in this setting.
Keywords: Approved tyrosine kinase inhibitors, efficacy data, experimental tyrosine kinase inhibitors, gastrointestinal cancers, personalized treatment.
Current Cancer Drug Targets
Title:Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment
Volume: 16 Issue: 2
Author(s): Erika Giordani, Federica Zoratto, Martina Strudel, Anselmo Papa, Luigi Rossi, Marina Minozzi, Davide Caruso, Eleonora Zaccarelli, Monica Verrico and Silverio Tomao
Affiliation:
Keywords: Approved tyrosine kinase inhibitors, efficacy data, experimental tyrosine kinase inhibitors, gastrointestinal cancers, personalized treatment.
Abstract: Gastrointestinal cancer treatment is based more on molecular biology that has provided increasing knowledge about cancer pathogenesis on which targeted therapy is being developed. Precisely, targeted therapy is defined as a “type of treatment that uses drugs, such as monoclonal antibodies or tyrosine kinase inhibitors, to identify and attack specific cancer cells”. Nowadays, the United States Food and Drug Administration has approved many targeted therapies for gastrointestinal cancer treatment, as many are in various phases of development as well. In a previous review we discussed the main monoclonal antibodies used and studied in gastrointestinal cancer. In addition to monoclonal antibodies, tyrosine kinase inhibitors represent another class of targeted therapy and following the approval of imatinib for gastrointestinal stromal tumours, other tyrosine kinase inhibitors have been approved for gastrointestinal cancers treatment such as sunitinib, regoragenib, sorafenib and erlotinib. Moving forward, the purpose of this review is to focus on the efficacy data of main tyrosine kinase inhibitors commonly used in the personalized treatment of each gastrointestinal tumour and to provide a comprehensive overview about experimental targeted therapies ongoing in this setting.
Export Options
About this article
Cite this article as:
Giordani Erika, Zoratto Federica, Strudel Martina, Papa Anselmo, Rossi Luigi, Minozzi Marina, Caruso Davide, Zaccarelli Eleonora, Verrico Monica and Tomao Silverio, Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment, Current Cancer Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1568009615666150817120712
DOI https://dx.doi.org/10.2174/1568009615666150817120712 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Synthesis of Nano-Doxorubicin and its Anticancer Effect
Anti-Cancer Agents in Medicinal Chemistry May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials
Anti-Cancer Agents in Medicinal Chemistry Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis
Current Gene Therapy Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy MicroRNA Levels in Cervical Cancer Samples and Relationship with Lesion Grade and HPV Infection
MicroRNA Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Notch-Associated MicroRNAs in Cancer
Current Drug Targets 11 Years of Cyanopyrrolidines as DPP-IV Inhibitors
Current Topics in Medicinal Chemistry Investigating the In Vivo Expression Patterns of miR-7 microRNA Family Members in the Adult Mouse Brain
MicroRNA Interstitial Lung Disease in Idiopathic Inflammatory Myopathy
Current Rheumatology Reviews Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets Fecal Microbiota Transplant: Latest Addition to Arsenal against Recurrent <i>Clostridium difficile</i> Infection
Recent Advances in Anti-Infective Drug Discovery Development of 96-microwell Plate Assay with Fluorescence Reader and HPLC Method with Fluorescence Detection for High-throughput Analysis of Linifanib in its Bulk and Dosage Forms
Current Pharmaceutical Analysis Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism